Ask Warren

KoBioLabs

348150 · KOSDAQ · ₩348150 · 고바이오랩

₩2,750▲ ₩135 (5.16%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
SellBuy

Filings

  • Half-year report (Jun 2026)반기보고서 (2026.06)Aug 13, 2026Open on DART
  • Quarterly report (Mar 2026)분기보고서 (2026.03)May 14, 2026Open on DART
  • Amended: Annual general meeting results[기재정정]정기주주총회결과Mar 27, 2026Open on DART
  • Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 27, 2026Open on DART
  • Change of CEO대표이사변경Mar 26, 2026Open on DART
  • Annual general meeting results정기주주총회결과Mar 26, 2026Open on DART
  • Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 26, 2026Open on DART
  • Major management matter relevant to investors투자판단관련주요경영사항 (마이크로바이옴 장질환 신약 후보물질 License out 계약 체결)Mar 25, 2026Open on DART
  • Amended attachment: Annual report (Dec 2025)[첨부정정]사업보고서 (2025.12)Mar 20, 2026Open on DART
  • Annual report (Dec 2025)사업보고서 (2025.12)Mar 19, 2026Open on DART
  • Audit report submitted감사보고서제출Mar 18, 2026Open on DART
  • Shareholders' meeting called주주총회소집결의Mar 11, 2026Open on DART
  • Notice of shareholders' meeting주주총회소집공고Mar 11, 2026Open on DART
  • Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 11, 2026Open on DART
  • Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2025Open on DART
  • Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 13, 2025Open on DART
  • Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
  • Quarterly report (Mar 2025)분기보고서 (2025.03)May 15, 2025Open on DART
  • Annual general meeting results정기주주총회결과Mar 31, 2025Open on DART
  • [Amended Filing] Notice on Appointment, Dismissal or Mid-Term Departure of Independent Director[기재정정]독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 31, 2025Open on DART
  • Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 31, 2025Open on DART
  • Audit report submitted감사보고서제출Mar 20, 2025Open on DART
  • Annual report (Dec 2024)사업보고서 (2024.12)Mar 20, 2025Open on DART
  • Notice of shareholders' meeting주주총회소집공고Mar 14, 2025Open on DART
  • Shareholders' meeting called주주총회소집결의Mar 6, 2025Open on DART
  • Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 14, 2025Open on DART
  • Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 13, 2024Open on DART
  • Quarterly report (Sep 2024)분기보고서 (2024.09)Nov 14, 2024Open on DART
  • Amended: Half-year report (Jun 2024)[기재정정]반기보고서 (2024.06)Nov 14, 2024Open on DART
  • Amended: Quarterly report (Mar 2024)[기재정정]분기보고서 (2024.03)Nov 14, 2024Open on DART
  • Amended: Annual report (Dec 2023)[기재정정]사업보고서 (2023.12)Nov 14, 2024Open on DART
  • Half-year report (Jun 2024)반기보고서 (2024.06)Aug 14, 2024Open on DART
  • Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) Before Maturity After Issuance (2nd Series)전환사채(해외전환사채포함)발행후만기전사채취득 (제2회차)Jun 28, 2024Open on DART
  • Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서May 31, 2024Open on DART
  • 5%+ holding report주식등의대량보유상황보고서(일반)May 31, 2024Open on DART
  • Acquisition of Bonds Before Maturity After Issuance of Convertible Bonds (incl. Overseas Convertible Bonds) (1st Series)전환사채(해외전환사채포함)발행후만기전사채취득 (제1회차)May 20, 2024Open on DART
  • Quarterly report (Mar 2024)분기보고서 (2024.03)May 3, 2024Open on DART
  • Annual general meeting results정기주주총회결과Mar 28, 2024Open on DART
  • Audit report submitted감사보고서제출Mar 20, 2024Open on DART
  • Annual report (Dec 2023)사업보고서 (2023.12)Mar 20, 2024Open on DART
  • Notice of shareholders' meeting주주총회소집공고Mar 13, 2024Open on DART
  • Shareholders' meeting called주주총회소집결의Mar 6, 2024Open on DART
  • 매출액또는손익구조30%(대규모법인은15%)이상변동Feb 14, 2024Open on DART
  • Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과)(중등도 판상형 건선 환자에서 KBL697의 유효성 및 안전성을 평가하는 2상 임상시험 Topline Data 수령)Dec 22, 2023Open on DART
  • 주주명부폐쇄기간또는기준일설정Dec 15, 2023Open on DART
  • Quarterly report (Sep 2023)분기보고서 (2023.09)Nov 14, 2023Open on DART
  • Half-year report (Jun 2023)반기보고서 (2023.06)Aug 14, 2023Open on DART
  • Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획자진취하등)(마이크로바이옴 신약 KBL697(궤양성 대장염) 미국FDA 및 식품의약품안전처 2a 임상시험 자진취하)Jul 28, 2023Open on DART
  • Major management matter relevant to investors투자판단관련주요경영사항(마이크로바이옴 신약 후보물질 기술이전 계약 해지 및 권리 반환)Jul 6, 2023Open on DART
  • 주식매수선택권부여에관한신고May 16, 2023Open on DART

Titles in Korean until English translations are added.

Also known as: KoBioLabs / 고바이오랩 / 348150 / KRX:348150

Source: KRX statistical information